
Background and aims: Patients who previously had a normal colonoscopy may subsequently undergo colorectal cancer (CRC) screening with multitarget stool DNA (mt-sDNA) testing. The yield of advanced neoplasia following a positive mt-sDNA test in this subgroup is not well defined. We compared colonoscopy outcomes after positive mt-sDNA tests in patients with and without a prior normal colonoscopy. Methods: We conducted a registry-based analysis using data from the population-based New Hampshire Colonoscopy Registry (NHCR). The primary outcome was an ordered four-level categorical variable reflecting colonoscopy findings: CRC, advanced colorectal neoplasia, non-advanced colorectal neoplasia, and no neoplasia. Ordinal logistic regression models were used to evaluate the association between prior normal colonoscopy and severity of findings. Results: Patients with a prior normal colonoscopy (n=739) were approximately half as likely to have more advanced findings compared with patients without a prior colonoscopy (n=994); prior normal colonoscopy was associated with lower odds of more advanced versus less advanced outcomes (OR 0.51; 95% CI 0.41–0.62; P < 0.001). However, the absolute prevalence of advanced colorectal neoplasia among patients with a previous colonoscopy remained substantial (19.1%; 95% CI 16.3–22.1%). Conclusions: Although prior normal colonoscopy is associated with lower odds of advanced findings after a positive mt-sDNA test, the residual prevalence of advanced neoplasia remains clinically meaningful. Regardless of prior screening history, there is a high yield of neoplasia, which could be attributed in part due to missed lesions on the prior colonoscopy. Our data provide potential benchmarks for expected lesion yield in this population.
Introduction: Obstructive sleep apnea (OSA) and gastroesophageal reflux disease (GERD) are prevalent conditions that can lead to significant medical complications. Both are conditions associated with sleep, with nocturnal gastroesophageal reflux (nGER) being one of the most common symptoms of GERD. There is variation in the reported prevalence of GERD in OSA patients across several studies. Thus, a summary of evidence related to disease prevalence from those studies is needed. This systematic review aimed to determine the pooled prevalence of GERD in patients with OSA and the prevalence of nGER, as well as to identify risk factors associated with GERD in adult patients with OSA. Methods: A systematic literature search was conducted in PubMed, the Cochrane Library, Scopus, CINAHL, and Web of Science for studies published up to April 2025. Studies reporting the prevalence of GERD in adult OSA patients were included. Data extraction and bias assessment were performed independently by two reviewers. A meta-analysis using the inverse variance method was used to summarize prevalence data from the included studies. Subgroup analyses were performed based on country and OSA diagnostic criteria. Age, diagnostic methods, body mass index (BMI), and Epworth Sleepiness Scale (ESS) scores were compared between the GERD and non-GERD groups. Results: A total of 33 studies comprising 12,076 patients were included to determine the pooled prevalence of GERD in OSA, which was found to be 34% (95% CI: 25–44, I 2 =98.2%). The prevalence of nGER in OSA was 43% (95% CI: 26–62, I 2 =98.0%). Subgroup analyses revealed that the prevalence of GERD in OSA was highest when GERD was diagnosed using 24-hour pH monitoring, at 56% (95% CI: 44–68). The highest prevalence of GERD was reported in Poland, at 76%. Three factors were significantly associated with GERD in patients with OSA: BMI, ESS score, and female sex. Conclusions: Approximately one-third of OSA patients had GERD. The highest prevalence of GERD was found in studies that used 24-hour pH monitoring. High ESS scores, high BMI, and female sex were associated with the presence of GERD in patients with OSA. The pooled estimates must be interpreted with caution due to high statistical heterogeneity, and the identified risk factors should be viewed with similar caution due to a limited number of studies.
Introduction: As ulcerative colitis (UC) advanced therapy (AT) options expand, understanding the benefit-risk trade-offs acceptable to patients and providers is increasingly important. Methods: A discrete choice experiment quantified preferences for six benefit-risk attributes of AT among patients with moderate-to-severe UC and providers in the US and Europe. Relative attribute importance (RAI), maximum acceptable risk (MAR), and simultaneous MAR thresholds (SMARTs) were calculated. Patient results were stratified by prior AT experience. Results: The combination of remission and corticosteroid-free remission at one year was most important to patients (N=557; RAI 40.1%) and providers (N=500; RAI 51.1%) followed by 5-year cancer risk (31.7% and 25.7%, respectively). Providers had a higher MAR for cancer than patients (4.0% vs 2.5%) and were willing to accept some higher joint risks of major adverse cardiovascular events (MACE) and cancer in exchange for increased probability of remission. Among AT-naïve patients, RAIs for remission and cancer risk were 36.0% and 35.3%, respectively, compared to 43.1% and 28.8% among AT-experienced patients. AT-experienced patients had a higher MAR for cancer versus AT-naïve patients (2.9% vs 1.8%) and were willing to accept some higher joint risks. Across all groups, when risks were considered jointly, risk tolerance decreased. Conclusions: Likelihood of remission and cancer risk were the most important to both patients and providers. Both groups were willing to make benefit-risk trade-offs, however, some differences emerged between patients and providers, and among patients by AT experience. Findings highlight the need for shared decision-making and communication about the complete benefit-risk profiles of AT options.
Background: Emerging evidence implicates heavy metals (HM) as environmental factors which may influence Crohn’s disease (CD) and ulcerative colitis (UC) pathogenesis. Methods: The present report includes two related studies. The first (‘serum-only’) compares HM serum levels (parts per billion, ppb) in people with CD and UC, including aluminum (Al), chromium (Cr), mercury (Hg), and titanium (Ti) compared to people with multiple sclerosis (MS) and healthy controls (HC). The second study correlated serum and tissue levels of HM in 18 persons undergoing colonoscopy and biopsy. Serum and intestinal biopsies of Al, Cr, Ti, and Hg concentrations were quantified using inductively coupled plasma mass spectrometry for both studies. Results: The serum-only study included 287 participants (CD (n=100), UC (n=50), MS (n=49), and HC (n= 88)). Versus HC, adjusted serum Al concentrations were higher in CD [fold change, 1.34; 95%CI (1.12–1.61)], lower in UC [0.64; 95%CI (0.51–0.80)], and lower in MS [0.76; 95%CI (0.60–0.97)]. Ti concentrations were lower in all three disease groups versus HC. Cr concentrations, higher in MS [2.34; 95% CI (1.59–3.45)], did not differ significantly between HC and either CD or UC. Hg concentrations were higher in both CD [2.17; 95%CI (1.52–3.09) and MS [1.62; 95%CI (1.02–2.59)]. In our small exploratory substudy, we found no statistically significant correlation between serum and intestinal tissue HM levels. Conclusion: Our report demonstrates differences in serum HM levels in people with CD relative to persons with UC or HC. Future research will benefit from the evaluation of these disparities and identification of potential implicated mechanisms.
Introduction: Esophageal squamous papillomas (ESPs) are rare epithelial lesions with an incompletely understood pathogenesis and uncertain malignant potential. Prior studies evaluating the association between ESP and human papillomavirus (HPV) have demonstrated conflicting results, often limited by small cohorts and heterogeneous HPV detection methodologies. Methods: We conducted a retrospective cohort study of histologically confirmed ESPs at Cleveland Clinic between January 2019 and July 2023. Clinical, endoscopic, and histopathologic data were collected. Formalin-fixed, paraffin-embedded tissue underwent RNA in situ hybridization (RNA ISH) targeting E6/E7 mRNA to detect transcriptionally active low- and high-risk HPV subtypes. Results: 184 ESP cases were identified, representing the largest single-center cohort. Lesions were predominantly solitary, small (<5 mm), and located in the mid-esophagus. GERD and dysphagia were the most common indications for endoscopy. No lesion demonstrated dysplasia, epidermoid metaplasia, or invasive carcinoma at index endoscopy. All evaluable lesions were negative for transcriptionally active HPV by RNA ISH (0/177; 95% CI, 0–2.1%). Follow-up endoscopy was available in 70 patients (38%), with a median follow-up of 24 months and surveillance extending to ≥4 years. No dysplasia / malignant transformation was observed during available follow-up. Persistent/residual ESP was identified in 6 patients following non-removal or biopsy-only sampling of the index lesion. Conclusions: The absence of transcriptionally active HPV supports a limited role for HPV in ESP pathogenesis and does not support routine HPV testing in typical, non-dysplastic ESPs. Our findings support the generally benign natural history of ESPs and highlight the need for prospective studies with standardized long-term surveillance to better define their malignant potential